

LISTING OF THE CLAIMS

Claims 1-20. (Cancelled)

21. (Previously presented) A method for treating or reducing the symptoms of gastroparesis in a patient comprising:

administering metoclopramide or a pharmaceutically acceptable salt thereof to a patient in need of gastroparesis treatment, wherein said metoclopramide is in a pharmaceutically acceptable nasal spray formulation and administered intranasally in a therapeutically effective amount at a daily dosage for about 2 weeks to about 8 weeks, so that one or more symptoms of gastroparesis is reduced.

B5
22. (Previously presented) The method of claim 21 wherein said daily dosage is administered for about 5 weeks to about 8 weeks.

23. (Previously presented) The method of claim 21 wherein said daily dosage is administered for about 6 weeks.

24. (Previously presented) The method of claim 21 wherein said daily dosage is between about 40 mg/day and about 160 mg/day.

25. (Previously presented) The method of claim 24 wherein said daily dosage is between about 40 mg/day and about 80 mg/day.

26. (Previously presented) The method of claim 24 wherein said daily dosage is about 40 mg/day.

27. (Previously presented) The method of claim 24 wherein said daily dosage is about 80 mg/day.

28. (Previously presented) The method of claim 21 wherein said daily dosage is between about 0.1 mg/kg to about 2.5 mg/kg.

29. (Previously presented) The method of claim 28, wherein said daily dosage is between about 0.6 mg/kg to about 1.2 mg/kg.

30. (Previously presented) A method for treating or reducing the symptoms of gastroparesis in a patient comprising:

administering metoclopramide or a pharmaceutically acceptable salt thereof to a patient in need of gastroparesis treatment, wherein said metoclopramide is in a pharmaceutically acceptable nasal formulation and administered intranasally as a spray or drops in a therapeutically effective amount at a daily dosage of between about 40 mg/day and about 160 mg/day, so that one or more symptoms of gastroparesis is reduced.

31. (Previously presented) The method of claim 30 wherein said daily dosage is between about 40 mg/day and about 80 mg/day.

32. (Previously presented) The method of claim 30 wherein said daily dosage is about 40 mg/day.

33. (Previously presented) The method of claim 30 wherein said daily dosage is about 80 mg/day.

34. (Previously presented) The method of claim 30 wherein said daily dosage is between about 0.1 mg/kg to about 2.5 mg/kg.

35. (Previously presented) The method of claim 34, wherein said daily dosage is between about 0.6 mg/kg to about 1.2 mg/kg.

36. (Previously presented) The method of claim 30 wherein said daily dosage is administered for about 2 weeks to about 8 weeks.

37. (Previously presented) The method of claim 30 wherein said daily dosage is administered for about 5 weeks to about 8 weeks.

38. (Previously presented) The method of claim 1 wherein said daily dosage is administered for about 6 weeks.

B5
Cont

39. (Previously presented) The method of claims 21 or 30 wherein said daily dosage is divided into 3 or 4 equal smaller doses and administered at equally spaced intervals within 24 hours.

40. (Previously presented) The method of claim 39 wherein the smaller doses are about 10 mg each.

41. (Previously presented) The method of claim 39 wherein the smaller doses are about 20 mg each.

42. (Previously presented) The method of claims 21 or 30 wherein said daily dosage is divided into 3 or 4 equal smaller doses and administered before meals.

43. (Previously presented) The method of claim 42 wherein said doses are administered before meals and before bedtime.

44. (Previously presented) The method of claim 42 wherein the smaller doses are about 10 mg each.

45. (Previously presented) The method of claim 42 wherein the smaller doses are about 20 mg each.

46. (Previously presented) The method of claims 21 or 30 wherein the metoclopramide or pharmaceutically acceptable salt thereof is in an aqueous-based carrier.

47. (Previously presented) The method of claims 21 or 30 wherein the metoclopramide or pharmaceutically acceptable salt thereof is in a sustained release formulation.

48. (Previously presented) The method of claims 21 or 30 wherein the metoclopramide or pharmaceutically acceptable salt thereof is co-administered with one or more additional drugs.

B5
cont

49. (Previously presented) The method of claims 21 or 30 wherein said dosage is administered for treating gastroparesis caused by any of: diabetes, a postviral syndrome, anorexia nervosa, surgery on the stomach or vagus nerve, a medication, gastroesophageal reflux disease, smooth muscle disorder, a nervous system disease, or a metabolic disorder.

50. (Previously presented) The method of claim 49 wherein said dosage is administered for treating gastroparesis caused by diabetes.

51. (Previously presented) The method of claim 50 wherein said diabetes is selected from the group consisting of type 1 diabetes and type 2 diabetes.

52. (Previously presented) The method of claim 49 wherein said medication is selected from the group consisting of: anticholinergics, and narcotics which slow contractions in the intestine.

B5
cont

53. (Previously presented) The method of claim 49 wherein said smooth muscle disorder is selected from the group consisting of: amyloidosis and scleroderma.

54. (Previously presented) The method of claim 49 wherein said nervous system disease is selected from the group consisting of: abdominal migraine and Parkinson's disease.

55. (Previously presented) The method of claim 49 wherein said metabolic disorder is hypothyroidism.

56 (New) The method of claim 42 wherein said daily dosage is administered for about 2 to 6 weeks.

57 (New) The method of claim 43 wherein said daily dosage is administered for about 2 to 6 weeks.

58 (New) The method of claim 44 wherein said daily dosage is administered for about 2 to 6 weeks.

59 (New) The method of claim 45 wherein said daily dosage is administered for about 2 to 6 weeks.

B5
cont
